Management believes that the presentation of these non-GAAP measuresprovides useful information to

Management believes that the presentation of these non-GAAP measuresprovides useful information to investors regarding the Company`s results ofoperations, as these non-GAAP measures allow investors to better evaluateongoing business performance. Investors should consider non-GAAP measures inaddition to, not as a substitute for, financial measures prepared in accordancewith GAAP. A reconciliation of the non-GAAP measures disclosed in the pressrelease with the most comparable GAAP measures are included in the financialtable attached to this press release. About RBC BearingsRBC Bearings Incorporated is an international manufacturer and marketer ofhighly engineered precision bearings and components.

Founded in 1919, theCompany is primarily focused on producing highly technical or regulated bearingproducts requiring sophisticated design, testing, and manufacturing capabilitiesfor the diversified industrial, aerospace and defense markets. Headquartered inOxford, Connecticut, RBC Bearings currently employs approximately 2,018 peopleand operates 22 manufacturing facilities in four countries. Althoughthe Company believes that the expectations reflected in any forward-lookingstatements are reasonable, actual results could differ materially from thoseprojected or assumed in any of our forward-looking statements. Our futurefinancial condition and results of operations, as well as any forward-lookingstatements, are subject to change and to inherent risks and uncertainties beyondthe control of the Company. TheCompany does not intend, and undertakes no obligation, to update or alter anyforward-looking statement. Bergeron, orFDMichael Cummings, Copyright Business Wire 2009.

CAROL STREAM, Ill.--(Business Wire)--It`s finally official: After years of M2M (machine-to-machine) companies walkingthe wilderness in search of mainstream validation, Brian J Quirke, director ofcommunications for the U.S Dept. of Energy (DOE) in the Midwest, stated thatthe smart grid is actually an M2M initiative. Quirke will be conducting aspecial seminar entitled "How to Benefit from Stimulus Dollars" during M2M`sConnected World (June 9-12, Chicago, IL) on guiding technology companies to takeadvantage of $38 billion in stimulus money earmarked for DOE projects. According to Quirke, "The smart grid is clearly an M2M initiative and the DOEwill be working with many companies to make this happen In the next 18 months,the U.S Dept. of Energy will invest approximately $38 billion to protect theenvironment and build the American economy using energy efficiency, renewableenergy, smart grid electricity, and clean fuels ? while creating the jobs thiscountry needs." Quirke will be speaking at 2 p.m on Wednesday June 10 duringthe event. He adds, "The Department has set these goals: Get good projectsunderway quickly ? in a way that creates lasting value; deliver an unprecedenteddegree of transparency; make a significant down payment on the nation`s energyand environmental future." With representatives and speakers from some of the country`s largest companies,this year`s M2M Connected World (June 9-12, Chicago, IL) is validation that M2Mhas entered the mainstream and hundreds of business professionals want to talkabout it. With M2M initiatives charted in fields ranging from managing fleets,to urban planning, to home healthcare, there are few industries that are nottouched by these technologies today.

"If any company is playing in or around the M2M space and is interested infinding out how the stimulus money is going to become available, Connected Worldis the only place to be on June 10. The validation of M2M as a recognizedinitiative by the current administration is a huge boost for our space," saysPeggy Smedley, publisher and editorial director of M2M magazine. Companies like Exelon, AGCO, RhiZone, Motorola, Verizon Wireless, SJE Rhombus,AT&T, MedApps, T-Mobile, Schlage, Cinterion Wireless Solutions, Hill-Rom,Zoombak, Tridium, Pacific Controls, Cooper Power Systems, Wavecom, andAlarm , will be in attendance to participate in and listen to three days ofpresentations on how companies are seeing definite return on investment from M2Mtechnologies. Collectively these companies make M2M Connected World the premier internationalgathering for M2M, smart services, wireless, telematics, and innovativecommunications companies, manufacturing and industrial adopters, thoughtleaders, technologists, and futurists. With the goal of helping companiesuncover ways to reduce costs and automate processes by networking their assets,M2M magazine helps companies turn data into actionable information. Visit M2Mmagazine on the Web at Please request media passes through Gen DiCola ofBIGfrontier:BIGfrontier for M2M magazineSteve Lundin (312) Copyright Business Wire 2009.

-- Phase 2 Clinical Study in Type 2 Diabetes Meets Primary Endpoint withStatistically Significant Reduction in FPG and Positive Trend in RelatedEfficacy Measures --CAMBRIDGE, Mass.--(Business Wire)--CombinatoRx, Incorporated (NASDAQ: CRXX) today reported positive results for itsPhase 2 clinical study of CRx-401 as an add-on to metformin therapy in Type 2diabetes. Results from this trial demonstrated that CRx-401 (a synergisticcombination of bezafibrate and diflunisal) performed statistically significantlybetter than bezafibrate on the primary efficacy endpoint of reduction in fastingplasma glucose (FPG) at day 90 with a difference of 12 mg/dL (p=0.049). Treatment GroupSubjectsMean change in FPG at Day 90 (ITT LOCF) CRx-401n=61-27 mg/dL Bezafibraten=59-15 mg/dL Difference favoring CRx-401-12 mg/dL (p=0.049)Consistent trends were observed in favor of CRx-401 on other supportive efficacyendpoints including glucose control, with reductions in HbA1c and homeostasismodel assessment of insulin resistance (HOMA-IR), and inflammatory control, witha reduction in C-reactive protein (CRP), providing a favorable overall impact onthe treatment of subjects with type 2 diabetes. In addition, CRx-401 treatmentwas associated with an expected reduction in serum triglyceride levels,consistent with the benefit of bezafibrate therapy. "We are encouraged to see that CRx-401 achieved statistically significant andclinically relevant reductions in FPG and a positive trend in other efficacymeasures including HOMA-IR," commented Alexis Borisy, President and CEO ofCombinatoRx. "CRx-401 demonstrated an ability to control glucose, lipids andinflammation, presenting a beneficial overall profile with the potential for thetreatment of type 2 diabetes and its associated co-morbidities. The positiveanti-diabetic efficacy results observed with CRx-401, coupled with a good safetyand tolerability profile, supports additional evaluation of CRx-401 in thetreatment of type 2 diabetes." The CRx-401 study enrolled 120 subjects with moderate to severe diabetes and wasdesigned to demonstrate the synergistic anti-diabetic activity of CRx-401compared to bezafibrate as an add-on to metformin therapy in subjects withpoorly controlled diabetes.